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A B S T R A C T
Background
People with serious mental illness have rates of Human Immuno-deficiency Virus (HIV) infection higher than expected in the general
population for the same demographic area. Despite this elevated prevalence, UK national strategies around sexual health and HIV
prevention do not state that people with serious mental illness are a high risk group. However, a significant proportion in this group are
sexually active and engage in HIV-risk behaviours including having multiple sexual partners, infrequent use of condoms and trading
sex for money or drugs. Therefore we propose the provision of HIV prevention advice could enhance the physical and social well being
of this population.
Objectives
To assess the effects of HIV prevention advice in reducing morbidity, mortality and preserving the quality of life in people with serious
mental illness.
Search methods
We searched the Cochrane Schizophrenia Group’s Trials Register (24 January 2012; 4 July 2016).
Selection criteria
We planned to include all randomised controlled trials focusing on HIV prevention advice versus standard care or comparing HIV
prevention advice with other more focused methods of delivering care or information for people with serious mental illness.
Data collection and analysis
Review authors (NW, AC, AA, GT) independently screened search results and did not identify any studies that fulfilled the review’s
criteria.
Main results
We did not identify any randomised studies that evaluated advice regarding HIV for people with serious mental illness. The excluded
studies illustrate that randomisation of packages of care relevant to both people with serious mental illness and HIV risk are possible.
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Authors’ conclusions
Policy makers, clinicians, researchers and service users need to collaborate to produce guidance on how best to provide advice for people
with serious mental illness in preventing the spread of HIV infection. It is entirely feasible that this could be within the context of a
well-designed simple large randomised study.
P L A I N L A N G U A G E S U M M A R Y
HIV prevention advice for people with serious mental illness
The human immunodeficiency virus (HIV) is a condition in humans in which our immune systems steadily begins to fail and allows
life-threatening infections and cancers. People with mental illness have higher than usual rates of HIV than in the general population.
Despite this, UK national strategies around sexual health and HIV prevention do not state that people with serious mental illness are
a high risk group. A significant number of people with mental health problems are sexually active and engage in HIV-risk behaviours
such as having multiple sexual partners, not using condoms and trading sex for money or drugs. In addition, during relapse, mental
illness may lead people to engage in practices they would not usually be engaged in.
The provision of HIV prevention advice could enhance the physical and social well being of people with mental health problems. HIV
health advice can take many forms. Advice is the active provision of information. It has an education component and is delivered in a
gentle and non-patronising manner. Advice from a healthcare professional can have a positive impact on behaviour and may motivate
people to seek further support and treatment.
The review’s aim was to assess the potential beneficial or harmful effects of HIV prevention advice in people with serious mental illness
(SMI). A search for randomised trials comparing HIV prevention advice with standard care for people with SMI was run in January
2012 and July 2016. However, no studies or trials were found. Policy makers, health professionals, researchers and people with mental
health problems need to collaborate to produce evidence-based guidance on how best to provide advice for people with serious mental
illness in preventing the spread of HIV. Better guidance and information about HIV in people with mental illness could be found by
conducting well-designed, simple and large studies on this important topic.
Ben Gray, Senior Peer Researcher, McPin Foundation. http://mcpin.org/
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
HIV ADVICE versus NO HIV ADVICE for people with serious mental illness
Patient or population: people with serious mental illness
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control HIV ADVICE versus NO
HIV ADVICE
HIV infection See comment See comment Not est imable 0
(0)
See comment We found no relevant
studies.
Quality of life: Im-
proved
Adverse events
Service use: Hospitali-
sation
Costs of care
Safe practice: 1.
Sexual practice/ knowl-
edge
Safe practice: 2. Nee-
dle practice/
knowledge
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B A C K G R O U N D
Description of the condition
The definition of severe mental illness with the widest consensus
is that of the US National Institute of Mental Health (NIMH)
(Schinnar 1990) and is based on diagnosis, duration and disability
(NIMH 1987). People with serious mental illness have conditions
such as schizophrenia or bipolar disorder, which last over a pro-
tracted period of time resulting in the erosion of functioning in
day to day life. A European survey put the total population-based
annual prevalence of serious mental illness at approximately two
per thousand (Ruggeri 2000). Evidence suggests that those with
serious mental illness have rates of Human Immuno-deficiency
Virus (HIV) infection which are higher than expected in the gen-
eral population in the same demographic area (Hughes 2009). The
current prevalence rate of HIV infection for the general popula-
tion in North America is 0.3%, which is marginally lower than
Europe (prevalence 0.4% - UNAIDS 2010). In contrast, studies
from the USA report prevalence rates of between 9% and 19%,
while in Europe 5% prevalence rates have been reported for people
with serious mental illness (Cournos 1991; Grassi 1999; Susser
1993). Despite this higher than expected prevalence, UK national
strategies around sexual health and HIV prevention do not state
that people with serious mental illness are a high risk group. How-
ever, a significant proportion in this group are sexually active and
engage in HIV-risk behaviours including having multiple sexual
partners, infrequent use of condoms and trading sex for money or
drugs (Rosenberg 2001). Additionally, during relapse, symptoms
of serious mental illness may lead people to engage in practices
they would not engage in if functioning at their optimum level
(Carey 2004).
Description of the intervention
HIV health advice can take many forms, depending on environ-
mental and socio-economic factors. Advice is the active provision
of preventative information; it has an educative component and is
delivered in a gentle non-patronising manner (Stott 1990). There-
fore, in this context it could be defined as any advice about HIV
health delivered by a healthcare professional.
How the intervention might work
Advice fromahealthcare professional canhave a positive impact on
behaviour (Kreuter 2000; Russell 1979) and may motivate people
to seek further support and treatment (Sutherland 2003). Given
the evidence of increased rates of potentially preventable health
problems in people with serious mental illness (Cournos 2005;
Dixon 1999; Robson 2007), and the suggestion that methodolog-
ically robust, healthy living interventions give “promising out-
comes” in people with schizophrenia (Bradshaw 2005), we believe
that appropriate HIV health advice could improve the quality of
life and increase life expectancy for sufferers of serious mental ill-
ness. HIV advice from a healthcare professional may encourage
those with seriousmental illness to; be sexually abstinent, delay the
initiation of sexual activity, decrease the numbers of sexual part-
ners, engage in the consistent and correct use of condoms (if they
are sexually active) and in harm reduction and needle exchange
programmes (if they are injecting drug users).
Why it is important to do this review
People with serious mental illness are some of the most vulnera-
ble and socially excluded members of society; the same could be
said for those with HIV. Therefore, the combination of both de-
bilitating conditions could have a profound social, psychological
and economic impact on individuals, their families and friends
(Hughes 2009). It has been identified that fewer than one in five
people at risk of HIV currently have access to infection prevention
(The Global HIV Prevention Working Group 2006). Given the
effects of serious mental illness and the difficulties this popula-
tion have in accessing general healthcare advice (Tosh 2010), it is
important that appropriate targeted advice is given to this group.
The completion of this review is required because there is no cure
or vaccination for HIV; the only way to prevent infection is by
the adoption of safer sexual and injection behaviours. We are not
aware of any systematic review that compares HIV advice-giving
interventions with standard care for people with serious mental
illness. This is one of a series of reviews (Table 1).
O B J E C T I V E S
To assess the effects of HIV prevention advice in reducing mor-
bidity, mortality and preserving the quality of life in people with
serious mental illness.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all relevant randomised controlled trials (RCTs),
and economic evaluations conducted alongside any potential
RCTs. Quasi-randomised studies, such as those allocating by us-
ing alternate days of the week were not eligible for inclusion. If we
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had encountered trials which suggested or implied the study was
randomised and where the demographic details of each group’s
participants were similar, we would have included them and con-
ducted a sensitivity analysis to evaluate the effect of the presence or
absence of these data. The study process is summarised in Figure
1.
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Figure 1. Study flow diagram.
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Types of participants
A requirement was that a majority of participants were within the
age range 18 to 65 years and suffering from serious mental ill-
ness, preferably as defined by National Institute of Mental Health
(NIMH 1987), but in the absence of that, from diagnosed illness
such as schizophrenia, schizophrenia-like disorders, bipolar disor-
der, or serious affective disorders. If the trials included participants
with a range of seriousmental illness wewould have included them
if the majority had schizophrenia; we would not have included
trials that only randomised people with bipolar or serious affective
disorders. We did not consider substance abuse to be a serious
mental illness in its own right, however, those trials dealing with
a dual diagnosis population i.e. those with serious mental illness
plus substance abuse were eligible. We did not include studies fo-
cusing on dementia, personality disorder and mental retardation,
as they were not covered by our definition of serious mental ill-
ness. Despite the fact that personality disorder is now included
in the NIMH definition, we excluded it from this review for the
following reasons; the diagnosis of personality disorder has low
interrater reliability (Zimmerman 1994); the duration of treat-
ment can be assessed much more precisely than duration of illness
(Schinnar 1990); there is insufficient information given on how to
operationalise the disability criterion in both the original NIMH
(NIMH 1987) definition and in the further work of Schinnar
1990.
Types of interventions
1. HIV prevention advice
It has been difficult to find a useful definition of ’advice’. In the
context of this review we have defined ‘advice’ as preventative
information (Greenlund 2002) or counsel (OED) that leaves the
recipient to make the final decision. Advice may be directional but
not paternalistic in its delivery. It is not a programmed or training
approach, focusing on the acquisition of knowledge, skills and
competencies as a result of formal teaching sessions. The effects
of programmes and/or training approaches for HIV prevention
in people with serious mental illness were not considered in this
review.
2. Standard care
Care in whichHIV advice is not specifically emphasised above and
beyond that which would be expected for people suffering from
serious mental illness.
Types of outcome measures
For the purposes of this review we planned to divide outcomes
into four time periods: i. immediate (within one week); ii. short
term (one week to six months); iii. medium term (six months to
one year); and iv. long term (more than one year).
Primary outcomes
1. HIV infection (any time period)
2. Risk-taking behaviour (short term)
2.1 Unprotected sex.
2.2 Sexual promiscuity.
2.3 Sharing needles for drug use.
Secondary outcomes
1. Adverse events
1.1 Number of participants with at least one adverse effect.
1.2 Clinically important specific adverse events (cardiac events,
death, movement disorders, prolactin increase and associated ef-
fects, weight gain, effects on white blood cell count).
1.3 Average endpoint specific adverse events score.
1.4 Average change in specific adverse events score.
1.5 Death - natural or suicide.
2. Service use
2.1 Hospital admission.
2.2 Emergency medical treatment.
2.3 Use of emergency services.
3. Financial dependency
3.1 Claiming unemployment benefit.
3.2 Claiming financial assistance because of a physical disability.
4. Social
4.1 Unemployment.
4.2 Social isolation as a result of preventable incapacity.
4.3 Increased burden to caregivers.
7HIV prevention advice for people with serious mental illness (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5. Quality of life
5.1 Loss of independence.
5.2 Loss of activities of daily living (ADL) skills.
5.3 Loss of earnings.
5.4 Loss of social status.
5.5 Healthy days.
6. Economic
6.1 Increased costs of health care.
6.2 Days off sick from work.
6.3 Reduced contribution to society.
6.4 Family claiming care allowance.
7. Leaving the study early (any reason, adverse events,
inefficacy of treatment)
8. Global state
8.1 Clinically important change in global state (as defined by in-
dividual studies).
8.2 Relapse (as defined by the individual studies).
9. Mental state (with particular reference to the positive and
negative symptoms of schizophrenia)
9.1 Clinically important change in general mental state score.
9.2 Average endpoint general mental score.
9.3 Average change in general mental state score.
9.4 Clinically important change in specific symptoms (positive
symptoms of schizophrenia, negative symptoms of schizophrenia).
9.5 Average endpoint specific symptom score.
9.6 Average change in specific symptom score.
10. Risk-taking behaviour
10.1 Unprotected sex (not short term).
10.2 Sexual promiscuity (not short term).
10.3 Sharing needles for drug use (not short term).
10.4 Sexually Transmitted Infection incidences.
10.5 Knowledge of HIV transmission routes.
11. Health behaviours
11.1 Behavioural intentions.
11.2 Behavioural intentions regarding safe needle practices.
12. ’Summary of findings’ table
We anticipated including the following outcomes in a ’Summary
of findings’ table:
12.1 HIV infection (measured by CD4+ count and viral load)
- Not using a condom.
- Number of casual sexual partners.
- Prevelance of needle sharing.
12.2 Quality of life
- Loss of independence.
- Loss of activities of daily living (ADL) skills.
- Loss of social status.
- Healthy days.
12.3 Adverse events
- Clinically important specific adverse effects (cardiac effects,
death, movement disorders, prolactin increase and associated ef-
fects, weight gain, effects on white blood cell count).
12.4 Service use
- Hospital admission.
12. 5 Leaving the study early
- Increased costs of health care.
12.6 Sexual health practices
- Sexually Transmitted Infection incidences - knowledge of HIV
transmission.
12.7 Safer needle practices
- Attitude towards safer needle practice.
- Behavioural intentions and safer needle intention.
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Study-Based Register of
Trials
On July 4, 2016, the information specialist searched the register
using the following search strategy:
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(*AIDS Education* OR *HIV Prevention*) in Intervention Field
OR *Human Immunodeficiency Virus (HIV)* in Health Care
Condition Field of STUDY
In such study-based register, searching the major concept retrieves
all the relevant keywords and studies because all the studies have
already been organised based on their interventions and linked to
the relevant topics.
The Cochrane Schizophrenia Group’s Register of Trials is com-
piled by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, EMBASE,MEDLINE, PsycINFO, PubMed,
and registries of clinical trials) and their monthly updates, hand-
searches, grey literature, and conference proceedings (see Group’s
Module). There is no language, date, document type, or publica-
tion status limitations for inclusion of records into the register.
For previous searches, please see Appendix 1.
Searching other resources
1. Reference searching
Had we found studies for inclusion in the review, the references
of all included studies would have been inspected to identify any
further relevant citations.
2. Personal contact
If we had found studies for inclusion in the review, the first author
of each studywould have been contacted for information regarding
unpublished trials.
Data collection and analysis
Selection of studies
Two review authors (NW, AC) screened the results of the elec-
tronic search. NW inspected all the abstracts of studies identified
through screening. To ensure reliability, GT and AA inspected a
random sample of these abstracts, comprising 10% of the total.
Where disagreement occurred, this was resolved by discussion, and
where there was still doubt, we acquired the full article for further
inspection. The full articles of relevant reports for reassessment
were carefully read for a final decision on inclusion (see Criteria
for considering studies for this review). In turn NW and AC read
all full reports and independently decided on whether they met
the inclusion criteria. We were not blinded to the names of the
authors, institutions or journal of publication. Where difficulties
or disputes arose, we asked author GT for help; if it was impossible
to decide, we added these studies to those awaiting assessment and
contacted the authors of the papers for clarification.
Data extraction and management
1. Extraction
If we had found relevant trials to include, we planned that two
review authors (NW and AC) would independently extract data
from the included studies.We would have discussed any disagree-
ment, documented our decisions and, if necessary, contacted the
authors of studies for clarification. Whenever possible, we would
have extracted data presented only in graphs and figures and in-
cluded the data if two review authors independently had the same
result. We would have attempted to contact authors through an
open-ended request, in order to obtain any missing information
or for clarification, whenever necessary. Where possible, we would
have extracted data relevant to each component centre of multi-
centre studies separately.
2. Management
2.1 Forms
If we had found relevant data to include, NW and AC would have
extracted it onto standard, simple forms.
2.2 Data from multi-centre trials
If we had found multi-centre trials to include, where possible,
the review authors would have independently verified calculated
centre data against original trial reports.
3. Scale-derived data
We would have included continuous data from rating scales only
if: a. the psychometric properties of the measuring instrument had
been described in a peer-reviewed journal (Marshall 2000); b. the
measuring instrument was not written or modified by one of the
trialists for that particular trial; and c. the measuring instrument
was either i. a self-report or ii. completed by an independent rater
or relative (not the therapist). Often this is not reported clearly,
but if we had encountered it this would have been noted in the
Description of studies.
4. Endpoint versus change data
We aimed to use scale endpoint data, which typically cannot have
negative values and is easier to interpret from a clinical point of
view. Change data are often not ordinal and are very problematic
to interpret. If endpoint data were unavailable, we intended to use
change data.
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5. Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying paramet-
ric tests to non-parametric data, we aimed to apply the follow-
ing standards to all data before inclusion: (a) standard deviations
(SDs) and means are reported in the paper or obtainable from the
authors; (b) when a scale starts from the finite number zero, the
SD, when multiplied by two, is less than the mean (as otherwise
the mean is unlikely to be an appropriate measure of the centre
of the distribution), (Altman 1996); (c) if a scale starts from a
positive value (such as PANSS (Positive and Negative Syndrome
Scale), which can have values from 30 to 210), we would have
modified the calculation described above to take the scale starting
point into account. In these cases skew is present if 2 SD > (SS
min), where S is the mean score and S min is the minimum score.
Endpoint scores on scales often have a finite start and endpoint
and these rules can be applied. When continuous data are pre-
sented on a scale which includes a possibility of negative values
(such as change data), it is difficult to tell whether data are skewed
or not. We planned to enter skewed data from studies of less than
200 participants in additional tables rather than into an analysis.
Skewed data pose less of a problem when looking at means if the
sample size is large, and we intended to enter skewed data from
large sample sizes into the syntheses.
6. Common measure
To facilitate comparison between trials, we intended to convert
variables that may have been reported in different metrics, such as
days in hospital, (mean days per year, per week or per month) to
a common metric (e.g. mean days per month).
7. Conversion of continuous to binary
Where possible, we planned to convert outcome measures to di-
chotomous data. This could be done by identifying cut-off points
on rating scales and dividing participants accordingly into ’clin-
ically improved’ or ’not clinically improved’. We would have as-
sumed that if there has been a 50% reduction in a scale-derived
score such as the Brief Psychiatric Rating Scale (Overall 1962) or
the Positive and Negative Syndrome Scale (Kay 1986; Kay 1987),
this would have been considered as a clinically significant response
(Leucht 2005; Leucht 2005a). If data based on these thresholds
were not available, we planned to use the primary cut-off presented
by the original authors.
8. Direction of graphs
Where possible, we planned to enter data in such away that the area
to the left of the line of no effect indicates a favourable outcome
for HIV advice.
Assessment of risk of bias in included studies
Again working independently, review authors NW and AC
planned to assess the risk of bias using the tool described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). This tool encourages consideration of how the sequence
was generated, how allocation was concealed, the integrity of
blinding at outcome, the completeness of outcome data, selective
reporting and other biases.We planned to exclude studies where
allocation was clearly not concealed. The risk of bias in each do-
main, and overall, would have been assessed and categorised into:
a. low risk of bias: plausible bias unlikely to seriously alter the
results (categorised as ’Yes’ in ’Risk of bias’ table); b. high risk of
bias: plausible bias that seriously weakens confidence in the results
(categorised as ’No’ in ’Risk of bias’ table); or c. unclear risk of bias:
plausible bias that raises some doubt about the results (categorised
as ’Unclear’ in ’Risk of bias’ table). We would not have included
trials with high risk of bias (defined as at least three out of five
domains categorised as ’No’) in the meta-analysis. If the raters dis-
agreed, the final rating would have been made by consensus with
the involvement of another member of the review group. If we had
considered that details of randomisation and other characteristics
of trials were inadequate, we would have contacted the authors of
the studies in order to obtain further information. We planned to
report non-concurrence in quality assessment.
Measures of treatment effect
1. Binary data
For binary outcomeswe planned to calculate a standard estimation
of the fixed-effect risk ratio (RR) and its 95% confidence interval
(CI). It has been shown that RR is more intuitive (Boissel 1999)
than odds ratios and that odds ratios tend to be interpreted as
RR by clinicians (Deeks 2000). Within the ’Summary of findings’
table we determined to calculate that the lowest control risk applies
to all data. We would have assumed the same for the highest risk
groups. We planned to use the ’Summary of findings’ table to
calculate absolute risk reduction for primary outcomes.
2. Continuous data
For continuous outcomes we planned to estimate a random-effects
mean difference (MD) between groups. We aimed not to calculate
effect size measures (standardised mean difference - SMD). How-
ever, in the case of where scales were of such similarity to allow,
presuming there was a small difference in measurement, we would
have calculated it and, whenever possible, transformed the effect
back to the units of one or more of the specific instruments.
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Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data pose problems. Firstly, authors often fail to account
for intra class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992) whereby P values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
Where clustering was not accounted for in primary studies, we
intended to present the data in a table, with a (*) symbol to indicate
the presence of a probable unit of analysis error. In subsequent
versions of this review we will seek to contact first authors of
studies to obtain intra-class correlation co-efficient (ICC) of their
clustered data and to adjust for this by using accepted methods
(Gulliford 1999). If clustering had been incorporated into the
analysis of primary studies, we intended to present these data as
if from a non-cluster randomised study, but would have adjusted
for the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants
per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (
Donner 2002). If the ICC had not been reported, we would have
assumedit to be 0.1 (Ukoumunne 1999).
Where cluster studies had been appropriately analysed, taking into
account the OCC and relevant data documented in the report,
synthesis with other studies may be possible using the generic
inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological or psycholog-
ical) of the treatment in the first phase is carried over to the second
phase. As a consequence, on entry to the second phase the par-
ticipants can differ systematically from their initial state despite a
wash-out phase. For the same reason, cross-over trials are not ap-
propriate if the condition of interest is unstable (Elbourne 2002).
As both effects are very likely in severe mental illness, we intended
to use only data from the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, if rele-
vant, we would have presented the additional treatment arms in
comparisons. If the additional treatment arms were not relevant,
we did not intend to reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). For any particular outcome with less than 50% of data
unaccounted, we did not intend to reproduce or use it within the
analyses. If, however, more than 50% of those in one arm of a
study are lost, but the total loss is less than 50%, we planned to
mark such data with ’*’ to indicate that such a result may be prone
to bias.
2. Binary
In the case where attrition for a binary outcome is between 0%
and 50% and where these data are not clearly described, we aimed
to present data on a ’once-randomised-always-analyse’ basis (an
intention-to-treat analysis). We would have assumed those lost
to follow-up had the same rates of negative outcome as those
who completed, with the exception of the outcome of death. We
planned to undertake a sensitivity analysis to test how prone the
primary outcomes were to change when ’completer’ data only
were compared to the intention-to-treat analysis using the above
assumption.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome was between
0% and 50% and completer-only data were reported, these would
have been reproduced.
3.2 Standard deviations
Where thereweremissingmeasures of variance for continuous data
but exact standard error and confidence intervals were available
for group means, and either P value or T value were available for
differences in mean, we intended to calculate a standard deviation
value according to the method described in Section 7.7.3 of the
Cochrane Handbook (Higgins 2011). If standard deviations were
not reported and could not be calculated from available data, we
would have asked authors to supply the data. In the absence of data
from authors, we would have used the mean standard deviation
from other studies.
3.3 Last observation carried forward
We anticipated that in some studies themethod of last observation
carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing
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data, LOCF introduces uncertainty about the reliability of the
results. Therefore, where LOCF data had been used in the trial,
if less than 50% of the data had been assumed, we would have
reproduced these data and indicated that they were the product of
LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
To judge clinical heterogeneity, we would have considered all in-
cluded studies, initially without seeing comparison data. We in-
tended to inspect all studies for clearly outlying situations or peo-
ple which we had not predicted would arise. If such situations or
participant groups arose we would have discussed these fully.
2. Methodological heterogeneity
All included studies would have been considered initially, without
seeing comparison data, to judge methodological heterogeneity.
We would have inspected all studies for clearly outlying methods
which we had not predicted would arise. If such methodological
outliers arose these would have been discussed fully.
3. Statistical
3.1 Visual inspection
We intended to visually inspect graphs to investigate the possibility
of statistical heterogeneity.
3.2 Employing the I2 statistic
We aimed to investigate heterogeneity between studies by consid-
ering the I2 method alongside the Chi2 P value. The I2 provides
an estimate of the percentage of inconsistency thought to be due
to chance (Higgins 2003). The importance of the observed value
of I2 depends on; a. magnitude and direction of effects and b.
strength of evidence for heterogeneity (e.g. P value from Chi2 test,
or a confidence interval for I2). We would have interpreted an I
2 estimate greater than or equal to 50% accompanied by a statis-
tically significant Chi2 statistic as evidence of substantial levels of
heterogeneity (Section 9.5.2 -Higgins 2011) and explored reasons
for heterogeneity. If the inconsistency was high and we had found
clear reasons, we would have presented the data separately.
Assessment of reporting biases
Reporting biases arise when the dissemination of research find-
ings is influenced by the nature and direction of results (Egger
1997). These are described in Section 10 of the Cochrane Hand-
book (Higgins 2011).We are aware that funnel plots may be useful
in investigating reporting biases but are of limited power to detect
small-study effects. We did not intend to use funnel plots for out-
comes where there were 10 or fewer studies, or where all studies
were of similar sizes. In other cases, where funnel plots were possi-
ble, we would have sought statistical advice in their interpretation.
Data synthesis
Where possible we would have employed a fixed-effect model
for analyses. We understand that there is no closed argument for
preference for use of fixed-effect or random-effects models. The
random-effects method incorporates an assumption that different
studies are estimating different, yet related, intervention effects.
This seems true. Random-effects methods, however, put added
weight onto the smaller of the studies - those studies that are likely
to carry most bias. The fixed-effect model is assumption-free and
we favoured using this model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
There are no included studies, therefore we have carried out no
subgroup analysis.
2. Investigation of heterogeneity
2.1 Unanticipated heterogeneity
Should unanticipated clinical or methodological heterogeneity
have become obvious, we would have simply stated hypotheses
regarding these for future reviews or versions of this review. There
are no included studies, therefore we have not undertaken analyses
relating to these.
2.2 Anticipated heterogeneity
We had anticipated some heterogeneity for the primary outcomes,
and so would have summarised all data but also presented them
separately.
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Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. For the primary
outcomes we intended to include these studies and if there was
no substantive difference when we added the implied randomised
studies to those with a better description of randomisation, we
would then have employed all data from these studies.
2. Assumptions for lost binary data
If assumptions needed to be made regarding people lost to follow-
up (see Dealing with missing data), we would have compared the
findings of the primary outcomes, where we used our assumption,
with completer data only. If there was a substantial difference, we
would have reported results and discussed them, but continued to
employ our assumption.
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
Results of the search
The initial search of the Cochrane Schizophrenia Group’s register
of trials in 2009 was a combined search designed to identify stud-
ies which would be relevant to physical health monitoring and
physical healthcare advice for people with serious mental illness.
One review based on this search has already been published (Tosh
2010) and work has begun on a series of sister reviews looking at
physical health advice for people with serious mental illness. One
review has been published which looks at general physical health
advice (Tosh 2011) and this is the second of several looking at
more targeted advice relating to specific problems or behaviours,
e.g. weight gain, smoking and oral health (Khokhar 2011). The
initial search identified 2382 references (from 1558 studies). After
examining all the reports, nine were suitable for further examina-
tion, all of which we had to exclude (Figure 1).
Included studies
No studies met the criteria for this review.
Excluded studies
Three studies were excluded on the basis that they were part of a
HIV Sex G programme (Berkman 2006; Berkman 2007; Susser
1998). Sex G (Sex, Games and Videotapes) is an intervention de-
signed to reduce sexual risk and was developed as a programme
for homeless mentally ill men in a New York City, NY shelter
that is built around activities central to shelter life: competitive
games, storytelling, and watching videos. For many of these men
sex is conducted in public spaces, revolves around drug use, and
must be conducted quickly. One component of the programme is
a competition to see which man can put a condom on a banana
fastest (without tearing the condom); this teaches important skills
for using a condom quickly. The program allows for sex issues to
be brought up in a nonjudgmental way (Susser 1994). Another
two were excluded on the basis that they were HIV education pro-
grammes running over several sessions, this constituted a struc-
tured programme of education rather than HIV advice (Collins
2001; Otto-Salaj 2001). Three more studies were excluded as they
were skills based trainingprogrammes, and, again, not advice (Katz
1996; Kelly 1997;Weinhardt 1998). The final paper was excluded
because it was an education programme undertaken at a day treat-
ment centre (Kern 1996a, see Characteristics of excluded studies).
Awaiting assessment
No studies await assessment.
Ongoing studies
We are not aware of any ongoing studies.
Risk of bias in included studies
There were no studies that fulfilled the criteria for inclusion. We
did not exclude any studies on the grounds of poor methodology.
Effects of interventions
See: Summary of findings for the main comparison HIV
ADVICE versus NO HIV ADVICE for people with serious
mental illness
Currently we know of no randomised studies describing HIV ad-
vice for people with serious mental illness.
D I S C U S S I O N
Summary of main results
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No studies met the inclusion criteria (Summary of findings for the
main comparison).
No trial-based guidance
Current medical practice, certainly in the UK, is led by guid-
ance from a number of professional and third-sector organisations,
who appear to base their advice on little more than anecdotal evi-
dence produced by working groups and stakeholder consultation.
The background literature summarised in support of this review
demonstrates that people with serious mental illness are at an in-
creased risk in comparison to the general population of contract-
ing HIV. Although the guidance at face value appears to make
sense, there are concerns around the implementation of something
which has little evidence to support it. It could be argued that
people with serious mental illness should expect that all aspects of
their care has been subjected to some degree of evaluation.
Overall completeness and applicability of
evidence
No studies met the inclusion criteria for this review.
Quality of the evidence
The nine studies we obtained for closer inspection were not ex-
cluded because of issues of quality. We were unable to find any
studies that were relevant, regardless of whether they were high or
poor quality.
Potential biases in the review process
The search criteria both in the Cochrane Schizophrenia Group
Trials Register (October 2009) and on our unsystematic search
(see:Searching other resources) should have been robust enough to
detect relevant studies. It is possible, however, that we have failed
to identify small studies but we think it unlikely that we would
have missed large trials. Studies published in languages other than
English, and those with equivocal results, are often difficult to
find (Egger 1997). Our search was biased by the use of English
phrases. However, given that the Cochrane Schizophrenia Group’s
Register covers many languages but is indexed in English we feel
that this would not have missed many studies within the register.
For example, the search uncovered 101 studies for which the title
was only available in Chinese characters. These were checked for
relevance by a Chinese speaking colleague (Jun Xia) and none were
identified as relevant to this review.
Agreements and disagreements with other
studies or reviews
We are not aware of any other similar reviews or studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with serious mental illness
We are unable to reach any conclusion as the excluded studies fo-
cused on HIV educational interventions, which cannot be classi-
fied as HIV preventative advice for reducing risk-taking behaviour
in individuals with serious mental illness. However, the fact that
we have not found any high quality evidence does not mean there
is no effect, merely that there are no eligible studies addressing this
issue. People with serious mental illness should recognise that the
advice given regarding HIV is well-intentioned but untested.
2. For clinicians
Clinicians and policy makers need to think about how HIV pre-
ventative advice is given to people with serious mental illness. In
the absence of randomised evidence it is not clear the best format
this advice should be and we would encourage clinicians to work
with researchers and service users to co-produce a well-designed
randomised controlled trial of a suitable intervention.
3. For policy makers
Policy makers are given little choice by the paucity of research but
to act on good will and hope that if they recommend provision of
advice regarding HIV, that it does no harm.
Implications for research
1. General
We could not identify any randomised trials that assessed the ef-
fects of HIV advice in people with serious mental illness, which
contradicts the view that current guidance and practice is based on
good intentions and expert opinion. Basing care only on evidence
from trials is not realistic (Cooper 2003; Tanenbaum 2005), how-
ever, many treatments or approaches that are not appropriately
evidenced are given to people, when it is possible to evaluate these
approaches. Healthcare professionals may be doing far more good
than they realise - or conversely far more harm. As part of a duty
of care, we argue, that ’what could be known, should be known’.
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2. Specific
2.1 Reviews
This review should be the focus of regular update. One new trial
will completely change the overview.
The excluded studies do suggest that a review on specific, active,
education packages regarding HIV for this group of people is indi-
cated. We suggest comparisons relevant to such a review in Table
2.
2.2 Trials
We realise that much thought and care goes into the design of
randomised studies. We have, however, also given this issue some
consideration and suggest a feasible design (Table 3).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Berkman 2006 Allocation: randomised.
Participants: schizophrenia, schizoaffective disorder, bipolar, major depressive disorder.
Intervention: ’SexG’ brief education intervention versus 2-hour standard HIV educational session, not focusing
on HIV advice
Berkman 2007 Allocation: randomised.
Participants: schizophrenia, schizoaffective disorder, bipolar with psychosis, major depression with psychosis.
Interventions: enhanced SexG education intervention versus money management intervention, not focusing on
HIV advice
Collins 2001 Allocation: randomised.
Participants: schizophrenia, schizoaffective disorder or bipolar disorder.
Intervention: education course versus educational presentation, not focusing on HIV advice
Katz 1996 Allocation: randomised.
Participants: schizophrenia or bipolar disorder.
Intervention: training sessions consisting of education and training, not focusing on HIV advice
Kelly 1997 Allocation: randomised.
Participants: mood disorder, schizophrenia or anxiety disorder.
Intervention: risk reduction education session versus skills group versus skills group plus advocacy, not focusing
on HIV advice
Kern 1996a Allocation: randomised.
Participants: seriously or chronically mentally ill who met diagnostic criteria within DSM-III-R (American Psy-
chiatric Association, 1987).
Intervention: AIDS education programme cross over trial, not focusing on HIV advice
Otto-Salaj 2001 Allocation: randomised.
Participants: seriously or chronically mentally ill who met diagnostic criteria within DSM-III-R (American Psy-
chiatric Association, 1987).
Intervention: 7-session small-group cognitive-behavioral HIV risk reduction intervention or a time-matched
comparison intervention, but not focused on HIV advice
Susser 1998 Allocation: randomised.
Participants: severe mental illness.
Intervention: SexG education intervention versus control intervention based on educational manual, not focusing
on HIV advice
Weinhardt 1998 Allocation: randomised.
Participants: schizophrenia spectrum disorder, bipolar disorder and major depressive disorder.
Interventions: education and training based on risk reduction and assertiveness training, not focusing on HIV
advice
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DSM-III-R: Diagnostic and Statistical Manual
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Series of related reviews
Title Reference
Physical health care monitoring Tosh 2010
General physical health advice Tosh 2011
Advice regarding smoking cessation Khanna 2012
Advice regarding oral health care Khokhar 2011
Advice regarding HIV/AIDs prevention This review
Advice regarding substance use Protocol in preparation
Table 2. Comparisons which were the focus of the excluded studies
Comparison Excluded study
Educational courses
versus training course Katz 1996; Kern 1996a; Weinhardt 1998
financial incentive Berkman 2007
educational presentation/manual Collins 2001; Susser 1998
different education course Otto-Salaj 2001
skills group Kelly 1997
skills group + advocacy Kelly 1997
Duration of educational course
- Brief HIV education course vs standard HIV
course
Berkman 2006
HIV Advocacy
- Skills group + advocacy vs skills group alone Kelly 1997
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Table 3. Suggested trial design
Method Allocation: randomised, clearly described.
Blinding: single - particular to specific outcomes (see below).
Duration: 6 months.
Participants Diagnosis: schizophrenia, or any serious mental illness.
N = 300.*
Age: any.
Sex: both.
History: any.
Intervention 1. Health promotion HIV Advice Checklist (Adapted version of the NAPWA 2012 checklist guide for people living
with HIV) administered by Care Co-ordinator.
2. Standard care: administered by Care Co-ordinator.
Outcomes HIV infection (any time period).
Risk-taking behaviour (short term).
Improve physical health (unprotected sex, sexual promiscuity, sharing needles for drug use)
Mental state - no clinically important change in general mental state
Economic outcomes.
Leaving the study early - reason.
Adverse vents - clinically important adverse events.
Notes * For 20% difference between groups for a binary outcome to be highlighted with reasonable degree of confidence
150 people are needed per group
A P P E N D I C E S
Appendix 1. Previous searches
Search in 2012
Electronic searches
1. Cochrane Schizophrenia Group’s Trials Register
The Trials Search Co-ordinator (TSC) searched the Cochrane Schizophrenia Group’s Registry of Trials (24 January, 2012) using the
following search strategies:
(*physical* or *cardio* or *metabolic* or *weight* or *HIV* or *AIDS* or *Tobacc* or *Smok* or *sex* or *medical* or *dental*
or *alcohol* or *oral* or *vision* or *sight*or *hearing* or *nutrition* or *advice* or *monitor*) in Title of REFERENCE AND
(*education* or *health promot* or *preventi* or *motivate* or *advice* or *monitor*) in Interventions of STUDY
The Cochrane Schizophrenia Group’s Registry of Trials is compiled by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, hand-
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searches, grey literature, and conference proceedings (see Group’s Module). There is no language, date, document type, or publication
status limitations for inclusion of records into the register.
Searching other resources
1. Reference searching
Had we found studies for inclusion in the review, the references of all included studies would have been inspected to identify any further
relevant citations.
2. Personal contact
If we had found studies for inclusion in the review, the first author of each study would have been contacted for information regarding
unpublished trials.
WH A T ’ S N E W
Last assessed as up-to-date: 4 July 2016.
Date Event Description
8 July 2016 New citation required but conclusions have not changed No new studies found, conclusions not changed.
4 July 2016 New search has been performed Search updated, no new study identified.
C O N T R I B U T I O N S O F A U T H O R S
Nicola Wright - protocol writing, primary review author, results and discussion writing.
Andrew Clifton - protocol writing, primary review author, results and discussion writing.
Athfah Akhtar - protocol writing, primary review author, results and discussion writing.
Graeme Tosh - project initiation, protocol writing, results and discussion writing.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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S O U R C E S O F S U P P O R T
Internal sources
• East Midlands Workforce Deanery, Nottingham, UK.
• NIHR CLAHRC-NDL, University of Nottingham, UK.
• Huddersfield University, UK.
• University of Nottingham, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
None known.
N O T E S
None.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Sexual Behavior; HIV Infections [∗prevention & control]; Mental Disorders [∗complications]
MeSH check words
Humans
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